phase III clinical study
Agilent, Transcenta Ink CDx Development Deal for Stomach Cancer Therapy Trial
The immunohistochemistry assay will be used to aid patient selection for a Phase III clinical trial of osemitamab plus Opdivo (nivolumab) and chemotherapy.
Burning Rock Biotech, Impact Therapeutics Partner on CDx for PARP Inhibitor Senaparib
The NGS firm will work with Impact to develop companion diagnostics to select patients eligible for Impact's synthetic lethality drugs, beginning with senaparib.
Adaptive Biotechnologies, Genentech Partner on MRD Testing in Venetoclax Clinical Trial
Genentech will use Adaptive's ClonoSeq assay for MRD testing in a CLL study. Adaptive will receive upfront and sample testing payments of undisclosed amounts.